15 enrolling by invitation. 15 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 15 | Enrolling by invitation 15 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer • Biological: GYNORYLAQ-TM Personalized Neoantigenic Peptide Vaccine - Endometrial Carcinoma, Endometrial Carcinoma Stage III | Early Phase 1 | Enrolling by invitation | Biogenea Pharmaceuticals Ltd. | 40 | 2026-02-02 | 2026-01-07 |
| Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer Microlyvaq™ (Personalized Multi-Epitope Immunotherapeutic) - NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification | Early Phase 1 | Enrolling by invitation | Biogenea Pharmaceuticals Ltd. | 90 | 2026-02-02 | 2025-12-16 |
| Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy Step-up therapy, Standard treatment Routine treatment - Esophageal Cancer, MRD | Early Phase 1 | Enrolling by invitation | The First Affiliated Hospital with Nanjing Medical University | 65 | 2025-12-20 | 2026-01-27 |
| Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors Oncolytic Virus injection(IDOV-Immune) - Cancer | Early Phase 1 | Enrolling by invitation | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 19 | 2025-12-18 | 2026-06-18 |
| Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors [68Ga]Ga-NOTA-RF - Pituitary Neoplasms | Early Phase 1 | Enrolling by invitation | Peking Union Medical College Hospital | 30 | 2025-11-17 | 2025-11-28 |
| Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma Microdevice - Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma | Early Phase 1 | Enrolling by invitation | Oliver Jonas | 25 | 2025-10-01 | 2026-05-18 |
| PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors 89Zr-LNCab104, 89Zr-LNCab103, 18F-FDG - Breast Cancer, Gastric Cancer (GC) | Early Phase 1 | Enrolling by invitation | Affiliated Hospital of Jiangnan University | 10 | 2025-07-01 | 2025-06-17 |
| The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies 18F-FDG, 89Zr-LNCab190, 89Zr-LNCab002 - Breast Cancer, Gastric Cancer (GC) | Early Phase 1 | Enrolling by invitation | Affiliated Hospital of Jiangnan University | 20 | 2025-07-01 | 2025-06-17 |
| Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Pucotenlimab Combined with Lenvatinib, Oxaliplatin plus S-1 regimen - Gastric (Stomach) Cancer | Early Phase 1 | Enrolling by invitation | Fujian Medical University | 100 | 2025-05-01 | 2026-01-21 |
| INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer iNK cells - Small Cell Lung Cancer | Early Phase 1 | Enrolling by invitation | Guangzhou Ruixin Biotechnological Co., LTD | 10 | 2024-12-15 | 2024-12-24 |
| Clinical Trial of Anovulatory Infertility a compound prescription of Chinese medicine - Polycystic Ovary Syndrome, Diminished Ovarian Reserve | Early Phase 1 | Enrolling by invitation | Affiliated Hospital of Nanjing University of Chinese Medicine | 650 | 2024-09-30 | 2025-02-11 |
| ⁶⁸Ga-DPA in the Lung Cancer Diagnosis 68Ga-DPA PET/CT - Lung Cancers | Early Phase 1 | Enrolling by invitation | Peking Union Medical College Hospital | 40 | 2024-09-28 | 2025-06-15 |
| [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer P17-079, P16-093, or P15-041 PET/CT - Metastatic Prostate Cancer (mPC) | Early Phase 1 | Enrolling by invitation | Peking Union Medical College Hospital | 40 | 2024-09-01 | 2025-03-07 |
| MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology - Colorectal Cancer | Early Phase 1 | Enrolling by invitation | Second Affiliated Hospital of Wenzhou Medical University | 10 | 2024-07-01 | 2026-04-28 |
| Pilot Trial for Treatment of Recurrent Glioblastoma Afatinib, Dasatinib, Palbociclib - Glioblastoma, Recurrent Disease | Early Phase 1 | Enrolling by invitation | AHS Cancer Control Alberta | 10 | 2023-06-27 | 2026-10-28 |
Stomach Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Transitional Cell (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1) · Pituitary Neoplasms (1) · Polycystic Ovary Syndrome (1) · Prostatic Neoplasms (1) · Recurrence (1)
Neoplasms by Site (11) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms by Histologic Type (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma (3) · Genital Diseases (3) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Stomach Diseases (3) · Thoracic Neoplasms (3)
Fluorodeoxyglucose F18 (2) · Afatinib (1) · Dasatinib (1) · Everolimus (1) · Oxaliplatin (1) · lenvatinib (1) · olaparib (1) · palbociclib (1)
Peking Union Medical College Hospital (3) · Affiliated Hospital of Jiangnan University (2) · Biogenea Pharmaceuticals Ltd. (2) · AHS Cancer Control Alberta (1) · Affiliated Hospital of Nanjing University of Chinese Medicine (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fujian Medical University (1) · Guangzhou Ruixin Biotechnological Co., LTD (1) · Oliver Jonas (1) · Second Affiliated Hospital of Wenzhou Medical University (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (11) · Greece (2) · Canada (1) · United States (1)
Paula de Robles (1) · Shuhang Wang (1) · Xianzhong Zhang (1) · Yu Guohua Guohua Yu, Director of the Cancer Dpartment (1) · Zhaohui Zhu (1)
PMID 25691612, PMID 33538338, PMID 35708168, PMID 36990609, PMID 40115982, PMID 40914168